Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Factors Influencing Drug Absorption: Disease States and Pharmacology01:25

Factors Influencing Drug Absorption: Disease States and Pharmacology

Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exploring the role of flow cytometry to assess endothelial cells in human sepsis: A systematic review.

Revista espanola de anestesiologia y reanimacion·2025
Same author

MIF is a common genetic determinant of COVID-19 symptomatic infection and severity.

QJM : monthly journal of the Association of Physicians·2022
Same author

Esophageal microbiome in active eosinophilic esophagitis and changes induced by different therapies.

Scientific reports·2021
Same author

Pulmonary artery pseudoaneurysms: endovascular management after adequate imaging diagnosis.

European radiology·2021
Same author

SOD1 p.D12Y variant is associated with amyotrophic lateral sclerosis/distal myopathy spectrum.

European journal of neurology·2020
Same author

Nanoemulsions and acidified milk gels as a strategy for improving stability and antioxidant activity of yarrow phenolic compounds after gastrointestinal digestion.

Food research international (Ottawa, Ont.)·2020

Related Experiment Video

Updated: Jun 3, 2026

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
10:27

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

Ascorbate-dependent decrease of the mucosal immune inflammatory response to gliadin in coeliac disease patients.

D Bernardo1, B Martínez-Abad, S Vallejo-Diez

  • 1Mucosal Immunology Lab, Department of Paediatrics & Immunology, Universidad de Valladolid-CSIC, Spain.

Allergologia Et Immunopathologia
|March 23, 2011
PubMed
Summary

Ascorbate (vitamin C) supplementation significantly reduced the mucosal immune response to gluten in coeliac disease (CD) patients. This suggests vitamin C may be a potential supplementary therapy for managing CD.

More Related Videos

Basic Three-Dimensional (3D) Intestinal Model System with an Immune Component
07:39

Basic Three-Dimensional (3D) Intestinal Model System with an Immune Component

Published on: September 1, 2023

Related Experiment Videos

Last Updated: Jun 3, 2026

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
10:27

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

Basic Three-Dimensional (3D) Intestinal Model System with an Immune Component
07:39

Basic Three-Dimensional (3D) Intestinal Model System with an Immune Component

Published on: September 1, 2023

Area of Science:

  • Immunology
  • Gastroenterology
  • Nutritional Science

Background:

  • The interleukin-15 (IL-15)/nuclear factor-kappa B (NF-κB) pathway is implicated in coeliac disease (CD) pathogenesis.
  • Ascorbate (vitamin C) is known to inhibit NF-κB activity.

Purpose of the Study:

  • To investigate the effect of ascorbate supplementation on the mucosal immune response to gliadin in coeliac disease.
  • To determine if ascorbate can down-regulate the IL-15/NF-κB axis in gliadin-stimulated CD intestinal biopsies.

Main Methods:

  • Duodenal biopsy explants from treated CD patients were cultured in vitro with or without gliadin and ascorbate.
  • Secretion levels of inflammatory mediators (nitrites, IFNγ, TNFα, IFNα, IL-17, IL-13, IL-6) and IL-15 were measured.

Main Results:

  • Ascorbate supplementation significantly inhibited the secretion of nitrites, IFNγ, TNFα, IFNα, and IL-6 in response to gliadin.
  • Ascorbate completely blocked gliadin-induced IL-15 production in CD patient biopsies.
  • These inhibitory effects were observed even in patients with basal IL-15 production.

Conclusions:

  • Ascorbate effectively decreases the mucosal inflammatory response to gluten in an intestinal biopsy culture model.
  • Ascorbate shows potential as a supplementary therapeutic agent for coeliac disease.